Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynogen reports positive results from Phase II IBS-d trial
In the randomized, double-blind, placebo controlled Phase II trial, 1mg dose of DDP225 administered once daily for eight weeks achieved a 71% response rate compared to a 25%
In the randomized, double-blind, placebo controlled Phase II trial, 1mg dose of DDP225 administered once daily for eight weeks achieved a 71% response rate compared to a 25%
The six-month patient crossover occurred when patients enrolled in the study switched from using a placebo to RPI-78M and those patients currently taking RPI-78M began using a placebo.
Collegium submitted its proposed pivotal Phase III clinical protocol to the FDA for its review and comment. After receiving positive feedback and reconfirming the basis of approval requirements,
Patients in the study are randomized on a 2:1 basis in favor of Xiaflex treatment. To qualify for the study, patients must have at least 20 degrees of
Despite the acceptance, the company continues to believe that its ANDA as originally filed met all the requirements for acceptance and thus will continue to pursue its administrative
In the study, treatment with the nanobody did not result in detectable immunogenicity. The study suggests that ALX-0081 adopts at least the plasma half-life of the target, von
In this study of 49 patients, the combination of Tykerb plus capecitabine (Xeloda) showed a reduction in HER2-positive breast cancer that had spread to the brain and had
In the international Acclaim trial, Celacade was shown to significantly reduce the risk of death or cardiovascular hospitalizations in large pre-specified subgroups of patients with chronic heart failure,
Under the terms of the agreement, Quest Pharma has already received $1,000,000; and the balance of $2,000,000 will be paid within the next twelve months. In return for
This agreement is said to make Siemens Medical Solutions Diagnostics the first in vitro diagnostics distributor of an automated TSH receptor antibody (TRAb) assay featuring stimulating TRAb KreLo